

The University of Western Ontario
BIOLOGICAL AGENTS REGISTRY FORM
Approved Biohazards Subcommittee: October 14, 2011
Biosafety Website: www.uwo.ca/humanresources/biosafety/

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario (UWO) or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biological agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biological agents being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Electronically completed forms are to be submitted to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190 or to jstanle2@uwo.ca) for distribution to the Biohazards Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or biosafety@uwo.ca. If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: www.uwo.ca/humanresources/biosafety/.

Please ensure that all questions are fully and clearly answered. Failure to do so will lead to the form being returned, which will cause delays in your approval and frustration for you and your colleagues on the Committee.

If you are re-submitting this form as requested by the Biohazards Subcommittee, please make modifications to the form in bold print, highlighted in yellow. Please re-submit forms electronically.

PRINCIPAL INVESTIGATOR:	Dr. Sean Cregan
DEPARTMENT:	Molecular Brain Research Group, Robarts Research
ADDRESS:	Rm 3250, 100 Perth Drive London ON N6A 5K8
PHONE NUMBER:	519-663-5777 Ext. Lab 24160 Office: 24134
EMERGENCY PHONE NUMBER(S):	Home: 519-642-2758, Cell: 226-448-2758
EMAIL:	scregan@robarts.ca

Location of experimental work to be carried out :

Building : Robarts research Institute	Room(s): 3250
Building : _____	Room(s): _____
Building : _____	Room(s): _____

***For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 15.0, Approvals).**

FUNDING AGENCY/AGENCIES: **HSF/CIHR**

GRANT TITLE(S): **Mechanisms of Bax activation in Neuronal Apoptosis, P53 Signaling in Oxidative Damage Induced Neuronal Apoptosis**

UNDERGRADUATE COURSE NAME(IF APPLICABLE): _____

List all personnel working under Principal Investigators supervision in this location:

<u>Name</u>	<u>UWO E-mail Address</u>	<u>Date of Biosafety Training</u>
Meera Karajgikar	mkarajgi@uwo.ca	April 2004
Jennifer Guadagno	jguadag2@uwo.ca	January 2010
Patrick Swan	pswan@uwo.ca	January 2006
Kristin Ambacher	kambache@uwo.ca	October 2008
Lisa Foris	lforis@uwo.ca	February 2012

**Please include a ONE page research summary or teaching protocol in lay terms.
Forms with summaries more than one page will not be reviewed.**

See Attachment 1

1.0 Microorganisms

1.1 Does your work involve the use of biological agents? YES NO
 (non-pathogenic and pathogenic biological agents including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA? YES NO

If YES, please give the name of the species _____

What is the origin of the microorganism(s)? _____

Please describe the risk (if any) of escape and how this will be mitigated:

Please attach the CFIA permit.

Please describe any CFIA permit conditions:

1.2 Please complete the table below:

Full Scientific Name of Biological Agent(s)* (Be specific)	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/ Supplier	PHAC or CFIA Containment Level
<i>E. coli DH5Alpha</i>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	500ml	invitrogen	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
<i>Adenovirus</i>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	500ml	Vector Biolabs	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3

*Please attach a Material Safety Data Sheet or equivalent from the supplier if the bacterium used is not on this link:
http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

Additional Comments: Attachment 2

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? YES NO
 (If NO, please proceed to Section 3.0)

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		Not applicable
Rodent	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Mouse Brain	2008-004-02
Non-human primate	<input type="checkbox"/> Yes <input type="checkbox"/> No		
Other (specify)	<input type="checkbox"/> Yes <input type="checkbox"/> No		

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Containment Level of each cell line	Supplier / Source of cell line(s)
Human	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	HEK 293	II	ATCC
Rodent	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	SH-SY5Y, N2A	II	ATCC
Non-human primate	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	COS-7	II	ATCC
Other (specify)	<input type="checkbox"/> Yes <input type="checkbox"/> No			

*Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see www.atcc.org)

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required 1 2 2+ 3

Additional Comments: See Attachment 3

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? YES NO
 If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/UNKNOWN	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Blood (fraction) or other Body Fluid		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (unpreserved)		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

Additional Comments: _____

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0? YES NO If NO, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done? YES, complete table below NO

Bacteria Used for Cloning *	Plasmid(s) **	Source of Plasmid	Gene Transformed or Transfected	Will there be a change due to transformation of the bacteria?	Will there be a change in the pathogenicity of the bacteria after the genetic modification?	What are the consequences due to the transformation of the bacteria?
<i>E. coli</i>						
DH5-alpha	See Attachment 4		See Attachment 4	Contains an antibiotic resistant plasmid	No	None

* Please attach a Material Safety Data Sheet or equivalent if available.

** Please attach a plasmid map.

***No Material Safety Data Sheet is required for the following strains of *E. coli*:

http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

4.3 Will genetic modification(s) of bacteria and/or cells involving viral vectors be made? YES, complete table below NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results from transduction
Adenovirus	See Attachment 2	Vector Biolabs	See attachment 2	See attachment 2

* Please attach a Material Safety Data Sheet or equivalent.

4.3.1 Will virus be replication defective? YES NO

4.3.2 Will virus be infectious to humans or animals? YES NO

4.3.3 Will this be expected to increase the containment level required? YES NO

5.0 Will genetic sequences from the following be involved?

- ◆ HIV NO YES, specify
- ◆ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens NO YES, specify
- ◆ SV 40 Large T antigen NO YES
- ◆ E1A oncogene NO YES
- ◆ Known oncogenes NO YES, specify
- ◆ Other human or animal pathogen and or their toxins NO YES, specify

5.1 Is any work being conducted with prions or prion sequences? NO YES

Additional Comments: Attachment 4

6.0 Human Gene Therapy Trials

6.1 Will human clinical trials be conducted involving a biological agent? YES NO
(including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)
If no, please proceed to Section 7.0

6.2 If YES, please specify which biological agent will be used:
Please attach a full description of the biological agent.

6.3 Will the biological agent be able to replicate in the host? YES NO

6.4 How will the biological agent be administered?

6.5 Please give the Health Care Facility where the clinical trial will be conducted:

6.6 Has human ethics approval been obtained? YES, number: NO PENDING

7.0 Animal Experiments

7.1 Will live animals be used? YES NO If NO, please proceed to section 8.0

7.2 Name of animal species to be used **Mouse**

7.3 AUS protocol # **2008-004-02**

7.4 List the location(s) for the animal experimentation and housing. **ACVS Rm 5543, RRI Room # 3241, 3250**

7.5 Will any of the agents listed in section 4.0 be used in live animals
 NO YES, specify:

7.6 Will the agent(s) be shed by the animal:
 YES NO, please justify:

8.0 Use of Animal species with Zoonotic Hazards

8.1 Will any animals with zoonotic hazards or their organs, tissues, lavages or other body fluids including blood be used (see list below)? YES NO - If NO, please proceed to section 9.0

8.2 Will live animals be used? YES NO

8.3 If YES, please specify the animal(s) used:

- ◆ Pound source dogs YES NO
- ◆ Pound source cats YES NO
- ◆ Cattle, sheep or goats YES, species NO
- ◆ Non-human primates YES, species NO
- ◆ Wild caught animals YES, species & colony # NO
- ◆ Birds YES, species NO
- ◆ Others (wild or domestic) YES, specify NO

8.4 If no live animals are used, please specify the source of the specimens:

9.0 Biological Toxins and Hormones

9.1 Will toxins or hormones of biological origin be used? YES NO If NO, please proceed to Section 10.0

9.2 If YES, please name the toxin(s) or hormones(s)
Please attach information, such as a Material Safety Data Sheet, for the toxin(s) used.

9.3 What is the LD₅₀ (specify species) of the toxin or hormone

9.4 How much of the toxin or hormone is handled at one time*?

9.5 How much of the toxin or hormone is stored*?

9.6 Will any biological toxins or hormones be used in live animals? YES NO
If YES, Please provide details:

*For information on biosecurity requirements, please see:
http://www.uwo.ca/humanresources/docandform/docs/healthandsafety/biosafety/Biosecurity_Requirements.pdf

Additional Comments: _____

10.0 Insects

10.1 Do you use insects? YES NO - If NO, please proceed to Section 11.0

10.2 If YES, please give the name of the species.

10.3 What is the origin of the insect?

10.4 What is the life stage of the insect?

10.5 What is your intention? Initiate and maintain colony, give location:
 "One-time" use, give location:

10.6 Please describe the risk (if any) of escape and how this will be mitigated:

10.7 Do you use insects that require a permit from the CFIA permit? YES NO
If YES, Please attach the CFIA permit & describe any CFIA permit conditions:

11.0 Plants

- 11.1 Do you use plants? YES NO - If NO, please proceed to Section 12.0
- 11.2 If YES, please give the name of the species.
- 11.3 What is the origin of the plant?
- 11.4 What is the form of the plant (seed, seedling, plant, tree...)?
- 11.5 What is your intention? Grow and maintain a crop "One-time" use
- 11.6 Do you do any modifications to the plant? YES NO
If yes, please describe:
- 11.7 Please describe the risk (if any) of loss of the material from the lab and how this will be mitigated:
- 11.8 Is the CFIA permit attached? YES NO
If YES, Please attach the CFIA permit & describe any CFIA permit conditions:

12.0 Import Requirements

- 12.1 Will any of the above agents be imported? YES, country of origin NO
If NO, please proceed to Section 13.0
- 12.2 Has an Import Permit been obtained from HC for human pathogens? YES NO
- 12.3 Has an import permit been obtained from CFIA for animal or plant pathogens? YES NO
- 12.4 Has the import permit been sent to OHS? YES, please provide permit # NO

13.0 Training Requirements for Personnel Named on Form

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS:

- ◆ Biosafety
- ◆ Laboratory and Environmental/Waste Management Safety
- ◆ WHMIS (Western or equivalent)
- ◆ Employee Health and Safety Orientation

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biological agents in Sections 1.0 to 9.0 have been trained.

An X in the check box indicates you agree with the above statement...
Enter Your Name Dr. Sean Cregan Date: April 18, 2012



14.0 Containment Levels

14.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required. 1 2 2+ 3

14.2 Has the facility been certified by OHS for this level of containment?
 YES, location and date of most recent biosafety inspection: *April 08, 2012.*
 NO, please certify
 NOT REQUIRED for Level 1 containment

14.3 Please indicate permit number (not applicable for first time applicants): **Bio-41-0027**

15.0 Procedures to be Followed

15.1 Are additional risk reduction measures necessary beyond containment level 1, 2, 2+ or 3 measures that are unique to these agents? YES NO
If YES please describe:

SEE E-mail

15.2 Please outline what will be done if there is an exposure, needlestick injury or an accidental splash:

15.3 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.shs.uwo.ca/workplace/workplacehealth.html>

An X in the check box indicates you agree with the above statement...
Enter Your Name Dr. Sean Cregan Date: April 18, 2012

Sean Cregan

15.4 Additional Comments: _____

16.0 Approvals

1) UWO Biohazards Subcommittee: SIGNATURE: _____
Date: _____

2) Safety Officer for the University of Western Ontario SIGNATURE: _____
Date: _____

3) Safety Officer for Institution where experiments will take place (if not UWO):
SIGNATURE: *Ronald Woodley*
Date: *May 29, 2012*

Approval Number: _____ Expiry Date (3 years from Approval): _____

Special Conditions of Approval:

Subject: Cregan BHARF
From: Ron Noseworthy <rnoseworthy@robarts.ca>
Date: 6/4/2012 8:45 AM
To: "jstanle2@uwo.ca" <jstanle2@uwo.ca>

-----Original Message-----

From: mkarajgikar [<mailto:mkarajgikar@robarts.ca>]
Sent: June-01-12 8:09 AM
To: Ron Noseworthy
Subject: Biosafety 2012

Hi Ron,

Here is the explanation for 15.2 in the biosafety renewal form:

In case of needlestick injury or an accidental splash; the worker should wash the exposed site with soap and water immediately. He must inform the supervisor of the incident. He must seek prompt medical attention at workplace health during the hours of operation or the nearest hospital emergency department or emergency clinic.

I apologize for missing this important information.

Meera Karajgikar



E-mail

Description of the project

Our laboratory is investigating the molecular mechanisms that regulate apoptotic cell death in the affected nervous system. Both caspases and Caspase-independent death effectors such as Apoptosis Inducing Factor (AIF) contribute to the neuronal cell death response. Furthermore, activation of both of these pathways is regulated by the pro-apoptotic Bcl-2 family protein Bax. The laboratory is currently examining the role of P53 and other injury inducible factors in the regulation of Bax activation using in vitro and in vivo models of neuronal injury.

Dr. Cregan's laboratory is also studying the molecular signaling pathways involved in the regulation of apoptosis in neural stem cells. The discovery of stem cells within the brain has led to much excitement as it is believed that these cells have the potential to regenerate damaged or diseased nervous tissue. However, the propensity of activated neural stem cells to undergo apoptosis has posed a major impediment to the success of such cell replacement therapies. Dr. Cregan's laboratory has developed a trophic factor deprivation model to study apoptosis in neural precursor cells. This research will lead to the identification of critical components of the apoptotic pathway in neural precursor cells which they will exploit to facilitate regeneration in the injured and diseased nervous system.

KEY RESEARCH ISSUES:

Define the molecular signaling pathways that regulate BAX activation and apoptosis following neuronal injury.

Identify the molecular processes involved in caspase-independent neuronal cell death.

Delineate the apoptotic signaling pathways in neural precursor cells.

Apoptosis is frequently triggered by events that alter the expression of key target genes. Under these circumstances, the genes involved can be identified by techniques that analyze gene expression.

Plasmids serve as important tools in genetics and biotechnology labs, where they are commonly used to express particular genes of interest. Plasmids are also used to express proteins to pursue further studies.

Adenoviral vectors are used to deliver genetic material into cells. This process can be performed into neurons as it is not possible to use plasmids in to neurons. Protein coding genes can be expressed using viral vectors, commonly to study the function of the particular protein.

In order to study the interaction between genes of interest, use of stable cell lines is very important. Cos 7 cells are used to study co-localization of two or more proteins using Confocal Microscopy. HEK 293 cells are used to study effect of different treatments before we proceed with primary cultures. SH-SY5Y and Neuro-2A cells are used as these are neuronal cell lines and it is more relevant to our laboratory's focus. To manipulate cells involves the introduction of foreign DNA by transfection. This is often performed to cause cells to

express a protein of interest. More recently, the transfection of Si-RNA constructs have been realized as a convenient mechanism for suppressing the expression of a particular gene/protein.

Attachment 2

Attachment 2

<i>transduction</i>				
Virus used for Transfection	Vector	Source of Vector	Gene Transfected	Change that results
Adenovirus	pAd-lox-GFP	Cell Biolabs	GFP	No change <i>express GFP</i>
Adenovirus	pAd-lox	David Park Lab	CDK-4	No change
Adenovirus	pAd-lox	David Park Lab	p-53	No change
Adenovirus	pAd-lox	David Park Lab	CDK-4 DN	No change
Adenovirus	pADTrack	David Park Lab	GSK-3-Beta	No change
Adenovirus	pADTrack	David Park Lab	GSK-3-Beta-CA	No change
Adenovirus	pADTrack	David Park Lab	FOXO-3CA	No change
Adenovirus	pADTrack	David Park Lab	Noxa	No change
Adenovirus	Adlox	David Park Lab	Rb-WT-IRES-GFP	No change
Adenovirus	Adlox	Cregan Lab	p53(22/23-53/54)	No change
Adenovirus	Adlox	Cregan Lab	HA-PUMA	No change
Adenovirus	Adlox	Cregan Lab	p53-173L	No change
Adenovirus	Adlox	Cregan Lab	dp1-WT	No change
Adenovirus	Adlox	Cregan Lab	p16	No change
Adenovirus	Adlox	Vector Biolabs	Cre-GFP	No change
Adenovirus	Adlox	Cregan Lab	ΔNp 73	No change
Adenovirus	Adlox	Cregan Lab	dn CDK6	No change
Adenovirus	Adlox	Cregan Lab	Flag-Mcl1	No change
Adenovirus	Adlox	Cregan Lab	dn-CDK2	No change
Adenovirus	Adlox	Cregan Lab	CDK6	No change
Adenovirus	Shuttle	Cregan Lab	Flag-Mcl1	No change

None of the adenoviruses will be injected into live animals (mice)

X/See Creg

Note: See revised attachment 2 attached.

Virus used for Transduction	Vector	Source of Vector	Gene Transfected	Change that results
Adenovirus	pAd-lox-GFP	Cell Biolabs	GFP	Express GFP
Adenovirus	pAd-lox	David Park Lab	CDK-4	Express CDK-4
Adenovirus	pAd-lox	David Park Lab	p-53	Express P-53
Adenovirus	pAd-lox	David Park Lab	CDK-4 DN	Express CDK-4 DN
Adenovirus	pADTrack	David Park Lab	GSK-3-Beta	Express GSK-3-Beta
Adenovirus	pADTrack	David Park Lab	GSK-3-Beta-CA	Express GSK-3-Beta-CA
Adenovirus	pADTrack	David Park Lab	FOXO-3CA	Express FOXO3-CA
Adenovirus	pADTrack	David Park Lab	Noxa	Express NOXA
Adenovirus	Adlox	David Park Lab	Rb-WT-IRES-GFP	Express GFP
Adenovirus	Adlox	Cregan Lab	p53(22/23-53/54)	Express P-53
Adenovirus	Adlox	Cregan Lab	HA-PUMA	Express PUMA
Adenovirus	Adlox	Cregan Lab	p53-173L	Express P-53
Adenovirus	Adlox	Cregan Lab	dp1-WT	Express GFP
Adenovirus	Adlox	Cregan Lab	p16	Express P-16
Adenovirus	Adlox	Vector Biolabs	Cre-GFP	Express GFP-Cre
Adenovirus	Adlox	Cregan Lab	Δ Np 73	Express DN P73
Adenovirus	Adlox	Cregan Lab	dn CDK6	Express DN-CDK-6
Adenovirus	Adlox	Cregan Lab	Flag-Mcl1	Express FLAG-MCL1
Adenovirus	Adlox	Cregan Lab	dn-CDK2	Express DN-CDK-2
Adenovirus	Adlox	Cregan Lab	CDK6	Express CDK-6



ll_òJll48vüθ→▼ { @Z@Zll♠::♥:: .çvll@U||♥Xl_üh■

GFP Recombinant Adenovirus

CATALOG NUMBER: ADV-004

STORAGE: -80°C

QUANTITY AND CONCENTRATION: 50 µl, 1 x 10¹¹ VP/mL in TBS containing 10% Glycerol**Background**

Recombinant adenoviruses have tremendous potential in both research and therapeutic applications. There are numerous advantages in using an adenovirus to introduce genetic material into host cells. The permissive host cell range is very wide. The virus has been used to infect many mammalian cell types (both replicative and non-replicative) for high expression of the recombinant protein. Recombinant adenoviruses are especially useful for gene transfer and protein expression in cell lines that have low transfection efficiency with liposome. After entering cells, the virus remains epichromosomal (i.e. does not integrate into the host chromosome so does not activate or inactivate host genes). Recently, recombinant adenoviruses have been used to deliver RNAi into cells.

Safety Consideration

Remember that you will be working with samples containing infectious virus. Follow the recommended NIH guidelines for all materials containing BSL-2 organisms. Always wear gloves, use filtered tips and work under a biosafety hood.

Methods

The appropriate amount of viruses used for infecting cells is critical for the outcome of your experiments. If not enough virus is used, it will not give 100% of infection. If too much virus is used, it will cause cytotoxicity or other undesired effects. The amount of adenovirus cell surface receptors vary greatly among different cell types therefore the optimal concentration differs dramatically between cell types. A range of 10-200 MOI (multiplicity of infection) is used for most cell lines, but up to 1000 MOI may be used for lymphoid cell lines.

Traditionally, Infectivity particles are measured in culture by a plaque-forming unit assay (PFU) that scores the number of viral plaques as a function of dilution. In contrast to the 10-day infection of a classical plaque assay, Cell Biolabs' QuickTiter™ Adenovirus Titer Immunoassay Kit (Cat. #VPK-109) only requires 2-day infection, and there is no agar overlay step. The kit antibody against hexon protein recognizes all serotypes of adenovirus by immunocytochemistry (see Flow Chart).




Y@J@R@T@...
Seed 293 cells in 24 or 12-well plate for 1 hr

↓
Prepare Adenovirus Serial Dilutions
and Infect 293 cells for 48 hrs

↓
Anti-Hexon Immunocytochemistry Staining

↓
Count Positive Cells and Calculate Viral Titer



References

1. Bett AJ, Haddara W, Prevec L and Graham FL. (1994) *Proc Natl Acad Sci U S A*. 91:8802-6.
2. Robbins, P. D., Tahara, H., and Ghivizzani, S. C. (1998) *Trends Biotechnol.* 16, 35-40.
3. Huang, S., Stupack, D., Mathias, P., Wang, Y., and Nemerow, G. (1997) *Proc. Natl. Acad. Sci. U S A*. 94, 8156-8161.
4. Bergelson, J. M., J. A. Cunningham, G. Droguett, E. A. Kurt-Jones, A. Krithivas, J. S. Hong, M. S. Horwitz, R. L. Crowell, and R. W. Finberg. (1997) *Science* 275:1320-1323.

Recent Product Citations

1. Perez-Moreno, M. et al. (2008). Loss of p120 catenin and links to mitotic alterations, inflammation, and skin cancer. *Proc. Natl. Acad. Sci. U S A* **105**:15399-15404.
2. Black, S.A. et al. (2008). TGFβ1 stimulates connective tissue growth factor (CCN2/CTGF) expression in human gingival fibroblasts through a RhoA-independent, Rac1/Cdc42-dependent mechanism: statins with forskolin block TGFβ1-induced CCN2/CTGF expression. *J. Biol. Chem.* **283**:10835-10847.
3. Jones, S.W. et al. (2009). Mitogen-activated protein kinase-activated protein kinase (MK2) modulates key biological pathways associated with OA disease pathology. *Osteoarthritis and Cartilage* **17**:124-131.

Warranty


These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

This product is for RESEARCH USE ONLY; not for use in diagnostic procedures.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2004-2009: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Material Safety Data Sheet

PRODUCT IDENTIFICATION

Catalog Number: ADV-xxx
Product Name: All Recombinant Adenoviruses

MANUFACTURER:

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126

EMERGENCY CONTACT:

+1 858 271 6500
info@cellbiolabs.com

SECTION I - INFECTIOUS AGENT

PRODUCT IDENTIFICATION:

All pre-made adenovirus made by Cell Biolabs.

BIOLOGICAL NAME: Adenovirus - Type 5

CHARACTERISTICS: Adenoviridae; non-enveloped, icosahedral virions, 75-80 nm diameter, doubledstranded, linear DNA genome. The recombinant viruses are based on human adenoviral backbone which is deleted in the essential E1 gene as well as the E3 gene. The viruses produced are thus non-replicative.

SECTION II - HEALTH HAZARD

PATHOGENICITY: Varies in clinical manifestation and severity; symptoms include fever, rhinitis, pharyngitis, cough and conjunctivitis. The risk from infection by defective recombinant adenoviral vectors depends both on the dose of virus and on the nature of the transgene. Adenovirus does not integrate into the host cell genome but can produce a strong immune response.

HOST RANGE: Humans and animals

INCUBATION PERIOD: from 1-10 days

MODE OF TRANSMISSION: In the laboratory, care must be taken to avoid spread of infectious material by aerosol, direct contact or accidental injection

CHEMICAL LISTED AS CARCINOGEN OR POTENTIAL CARCINOGEN: None

SECTION III - VIABILITY

DRUG SUSCEPTIBILITY: No specific antiviral available

SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to 1% sodium hypochlorite, 2% glutaraldehyde. Recommend use of 1/3 volume of bleach for 30 minutes.

PHYSICAL INACTIVATION: Sensitive to heat; 1 hour at 56°C is used to inactivate virus.

SURVIVAL OUTSIDE HOST: Adenovirus type 5 survived from 3-8 weeks on environmental surfaces at room temperature.

SECTION IV - MEDICAL

SURVEILLANCE: Monitor for symptoms; confirm by serological analysis

FIRST AID/TREATMENT:

Contact: Immediately flush eyes and skin with plenty of water for at least 15 minutes. Call a

7758 Arjons Drive, San Diego, CA 92126
Phone (858) 271 6500
US Toll Free (888) CBL 0505
Fax (858) 271 6514
info@cellbiolabs.com



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

physician.

Inhalation: N/A

Ingestion: Wash out mouth with water. Call a physician

Accidental injection: wash area with soap and water. Call a physician.

SECTION V - ACCIDENTAL RELEASE PROCEDURES

Pour 1 volume of Javel water over the leak(s) and wait for 15 minutes.

Wipe up carefully.

Hold for autoclave waste disposal and decontaminate work surfaces with 70% alcohol.

SECTION VI - RECOMMENDED PRECAUTIONS

CONTAINMENT REQUIREMENTS: Biosafety level 2 practices and containment facilities for all activities involving the virus and potentially infectious body fluids or tissues. This level consists of etiological agents considered to be of ordinary potential harm.

PROTECTIVE CLOTHING: Recombinants Adenovirus: Laboratory coat; gloves.

OTHER PRECAUTIONS:

Access to the laboratory is limited.

Work surfaces are decontaminated before and after each procedure

Mechanical pipetting devices are used for all procedures; mouth pipetting is prohibited.

Eating, drinking, and smoking are not permitted in the laboratory; food is not stored in laboratory areas.

Laboratory coats are worn in and are removed before leaving the laboratory.

Hands are washed before and after handling virus.

SECTION VII - HANDLING INFORMATION

DISPOSAL: Decontaminate all wastes before disposal; steam sterilization

STORAGE: In sealed containers that are appropriately labeled

SECTION VIII - MISCELLANEOUS INFORMATION

The above information and recommendations are believed to be accurate and represent the most complete information currently available to us. All materials and components may present unknown hazards and should be used with caution. Cell Biolabs, Inc assumes no liability resulting from use of the above products.

7758 Arjons Drive, San Diego, CA 92126
Phone (858) 271 6500
US Toll Free (888) CBL 0505
Fax (858) 271 6514
info@cellbiolabs.com

VECTOR BIOLABS

THE ADENOVIRUS COMPANY

User Manual for Ready-To-Use Recombinant Adenovirus

CONTENTS AND STORAGE

Recombinant adenovirus is supplied in liquid form at indicated titer. The storage solution is DMEM/2.5% glycerol. Store at -80°C. If desired, aliquot viral stock upon arrival, and store those aliquots at -80°C freezer immediately. **DO NOT FREEZE AND THAW REPEATEDLY.**

DESCRIPTION

Recombinant adenovirus is for delivering interested genes into mammalian cells. It provides the following advantages:

- (1) 100% efficiency of gene delivery in many cell types.
- (2) Recombinant viruses can be added directly to cells in culture medium (in the presence or absence of serum).
- (3) It is not necessary to remove viruses, change or add medium following infection, although viruses can be removed after 6-12 hours post infections.

IMPORTANT GUIDELINES

Follow these guidelines when performing infections:

1. Prepare virus-containing media:

Thaw viral stock at either room temperature or on ice.
Add desired amount of virus to media. If needed, viruses could be diluted further in DMEM or other media

2. Infecting cells with virus:

Remove the original cell culture media, and add the above virus-containing media to cell culture. Below is a general guideline for the amount of media used:

24-well plate:	0.2-0.3 ml
12-well plate:	0.5-0.8 ml
6-well plate:	1-1.5 ml/well
60mm-plate:	3-4 ml/plate
10cm-plate:	8-12 ml/plate

Incubate cells with the virus-containing media for 6-12 hours, or as long as you wish.
(Optional), you could remove virus-containing media and replace it with fresh, desired media.

The appropriate amount of viruses used for infecting cells is critical for the outcome of your experiments. The goal is to get 100% of infection without causing cytotoxicity or other undesired effects. The amount of adenovirus cell surface receptors vary greatly among different cell types therefore the optimal concentration differs dramatically between cell types. A range of 10-100 MOI (multiplicity of infection) is used for most cell lines, but up to 1000 MOI may be used for lymphoid cell lines.

To determine this optimal concentration of virus for your study, you could conduct pilot testing in your cell line by using reporter adenoviruses, such as β -gal adenovirus (Cat.#1080) or GFP adenovirus (Cat.#1060).

Date of revision: Jan. 30, 2005

VECTOR BIOLABS
THE ADENOVIRUS COMPANY

MATERIAL SAFETY DATA SHEET

EMERGENCY TELEPHONES: 1- 877-Biolabs 1-215-966-6045

<http://www.vectorbiolabs.com>

MATERIAL SAFETY DATA SHEET - INFECTIOUS SUBSTANCES

SECTION I - INFECTIOUS AGENT

PRODUCT IDENTIFICATION:

All pre-made adenovirus made by Vector BioLabs.

BIOLOGICAL NAME: Adenovirus - Type 5

CHARACTERISTICS: Adenoviridae; non-enveloped, icosahedral virions, 75-80 nm diameter, doublestranded, linear DNA genome. The recombinant viruses are based on human adenoviral backbone which is deleted in the essential E1 gene as well as the E3 gene. The viruses produced are thus non-replicative.

SECTION II - HEALTH HAZARD

PATHOGENICITY: Varies in clinical manifestation and severity; symptoms include fever, rhinitis, pharyngitis, cough and conjunctivitis. The risk from infection by defective recombinant adenoviral vectors depends both on the dose of virus and on the nature of the transgene. Adenovirus does not integrate into the host cell genome but can produce a strong immune response.

HOST RANGE: Humans and animals

INCUBATION PERIOD: from 1-10 days

MODE OF TRANSMISSION: In the laboratory, care must be taken to avoid spread of infectious material by aerosol, direct contact or accidental injection

CHEMICAL LISTED AS CARCINOGEN OR POTENTIAL CARCINOGEN: None

SECTION III - VIABILITY

DRUG SUSCEPTIBILITY: No specific antiviral available

SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to 1% sodium hypochlorite, 2% glutaraldehyde. Recommend use of 1/3 volume of bleach for 30 minutes.

PHYSICAL INACTIVATION: Sensitive to heat; 1 hour at 56°C is used to inactivate virus.

SURVIVAL OUTSIDE HOST: Adenovirus type 5 survived from 3-8 weeks on environmental surfaces at room temperature.

SECTION IV - MEDICAL

SURVEILLANCE: Monitor for symptoms; confirm by serological analysis

FIRST AID/TREATMENT:

Contact: Immediately flush eyes and skin with plenty of water for at least 15 minutes. Call a physician.

Inhalation: N/A

Ingestion: Wash out mouth with water. Call a physician

Accidental injection: wash area with soap and water. Call a physician.

SECTION V – ACCIDENTAL RELEASE PROCEDURES

Pour 1 volume of Javel water over the leak(s) and wait for 15 minutes.

Wipe up carefully.

Hold for autoclave waste disposal and decontaminate work surfaces with 70% alcohol.

SECTION VI - RECOMMENDED PRECAUTIONS

CONTAINMENT REQUIREMENTS: Biosafety level 2 practices and containment facilities for all activities involving the virus and potentially infectious body fluids or tissues. This level consists of etiological agents considered to be of ordinary potential harm.

PROTECTIVE CLOTHING: Recombinants Adenovirus: Laboratory coat; gloves.

OTHER PRECAUTIONS:

Access to the laboratory is limited.

Work surfaces are decontaminated before and after each procedure

Mechanical pipetting devices are used for all procedures; mouth pipetting is prohibited.

Eating, drinking, and smoking are not permitted in the laboratory; food is not stored in laboratory areas.

Laboratory coats are worn in and are removed before leaving the laboratory.

Hands are washed before and after handling virus.

SECTION VII - HANDLING INFORMATION

DISPOSAL: Decontaminate all wastes before disposal; steam sterilization

STORAGE: In sealed containers that are appropriately labeled

SECTION VIII - MISCELLANEOUS INFORMATION

The above information and recommendations are believed to be accurate and represent the most complete information currently available to us. All materials and components may present unknown hazards and should be used with caution. Vector BioLabs, Inc assumes no liability resulting from use of the above products.

Date of revision: May 24, 2004

Attachment 3

Cell Biology

ATCC® Number: **CRL-1651™**  Price: **\$264.00**
 Designations: **COS-7** Depositors: Y Gluzman
 Biosafety Level: 2 [Cells Contain SV-40 viral DNA sequences] Shipped: frozen
 Medium & Serum: See Propagation Growth Properties: adherent fibroblast
 Organism: *Cercopithecus aethiops* Morphology: 

Source: **Organ:** kidney
Cell Type: SV40 transformed

Cellular Products: T antigen

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Related Cell Culture Products

Applications: transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents)

Virus Susceptibility: SV40 (lytic growth); SV40 tsA209 at 40C; SV40 mutants with deletions in the early region

Comments: This is an African green monkey kidney fibroblast-like cell line suitable for transfection by vectors requiring expression of SV40 T antigen. This line contains T antigen, retains complete permissiveness for lytic growth of SV40, supports the replication of ts A209 virus at 40C, and supports the replication of pure populations of SV40 mutants with deletions in the early region. The line was derived from the CV-1 cell line (ATCC ® CCL-70?) by transformation with an origin defective mutant of SV40 which codes for wild type T antigen.

Propagation: **ATCC complete growth medium:** The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO₂), 5%
Temperature: 37.0°C

Protocol:

Subculturing:

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach

- may be placed at 37°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
 5. Add appropriate aliquots of the cell suspension to new culture vessels.
 6. Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:8 is recommended

Medium Renewal: 2 to 3 times per week

Preservation:

Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase

Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC [30-2002](#)

recommended serum: ATCC [30-2020](#)

Related Products:

parental cell line: ATCC [CCL-70](#)

0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca⁺⁺, Mg⁺⁺): ATCC [30-2101](#)

Cell culture tested DMSO: ATCC [4-X](#)

1822: Gluzman Y. SV40-transformed simian cells support the replication of early SV40 mutants. *Cell* 23: 175-182, 1981. PubMed: [6260373](#)

32447: Fernandez LM, Puett D. Lys583 in the third extracellular loop of the lutropin/choriogonadotropin receptor is critical for signaling. *J. Biol. Chem.* 271: 925-930, 1996. PubMed: [8557706](#)

32459: Maestrini E, et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. *Proc. Natl. Acad. Sci. USA* 93: 674-678, 1996. PubMed: [8570614](#)

32500: Campbell M, et al. The simian foamy virus type 1 transcriptional transactivator (Tas) binds and activates an enhancer element in the gag gene. *J. Virol.* 70: 6847-6855, 1996. PubMed: [8794326](#)

32502: Gonzalez Armas JC, et al. DNA immunization confers protection against murine cytomegalovirus infection. *J. Virol.* 70: 7921-7928, 1996. PubMed: [8892915](#)

References:

32547: Jang SI, et al. Activator protein 1 activity is involved in the regulation of the cell type-specific expression from the proximal promoter of the human profilaggrin gene. *J. Biol. Chem.* 271: 24105-24114, 1996. PubMed: [8798649](#)

32566: Dittrich E, et al. A di-leucine motif and an upstream serine in the interleukin-6 (IL-6) signal transducer gp130 mediate ligand-induced endocytosis and down-regulation of the IL-6 receptor. *J. Biol. Chem.* 271: 5487-5494, 1996. PubMed: [8621406](#)

32568: Lee JH, et al. The proximal promoter of the human transglutaminase 3 gene. *J. Biol. Chem.* 271: 4561-4568, 1996. PubMed: [8626812](#)

32720: Chen Y, et al. Demonstration of binding of dengue virus envelope protein to target cells. *J. Virol.* 70: 8765-8772, 1996. PubMed: [8971005](#)

32728: Russell DW, Miller AD. Foamy virus vectors. *J. Virol.* 70: 217-222, 1996. PubMed: [8523528](#)

32861: Wright DA, et al. Association of human fas (CD95) with a ubiquitin-conjugating enzyme (UBC-FAP). *J. Biol. Chem.* 271: 31037-31043, 1996. PubMed: [8940097](#)

32893: Zhang J, et al. Dynamin and beta-arrestin reveal distinct mechanisms for G protein-coupled receptor internalization. *J. Biol. Chem.* 271: 18302-18305, 1996.

Cell Biology

ATCC® Number: CCL-131™
Designations: Neuro-2a
Biosafety Level: 1
Medium & Serum: See Propagation



Price: \$256.00
Depositors: RJ Klebe
Shipped: frozen
Growth Properties: adherent neuronal and amoeboid stem cells

Organism: *Mus musculus* (mouse)

Morphology:

Source: Strain: A
Organ: brain
Disease: neuroblastoma
Cell Type: neuroblast;

Cellular Products: acetylcholinesterase
tubulin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Related Cell Culture Products

Applications: transfection host (technology from amaxa
Roche FuGENE® Transfection Reagents)

Virus Susceptibility: Herpes simplex virus
Vesicular stomatitis virus
Human poliovirus 1

Reverse Transcript: negative

Antigen Expression: H-2, a haplotype; *Mus musculus*, expressed
modal number = 95; range = 59 to 193.

Cytogenetic Analysis: Karyotype unstable within a stemline range of 94 to 98 chromosomes. All the cells contain 6 to 10 large chromosomes with median or submedian centromeres and 2 to 4 minute chromosomes.

Geno Type: albino

Comments: Clone Neuro-2a was established by R.J. Klebe and F.H. Ruddle from a spontaneous tumor of a strain A albino mouse. This tumor line, designated C1300, was obtained from the Jackson Laboratory, Bar Harbor, Maine [22161]. Neuro-2a cells produce large quantities of microtubular protein which is believed to play a role in a contractile system which is responsible for axoplasmic flow in nerve cells. The cell line has been used for studies on the mechanism of vinblastine precipitation of microtubular protein, the kinetics of GTP binding to isolated protein, the turnover of microtubules in vivo, and the synthesis and assembly of microtubular protein [PubMed: 5263744]. The World Organization for Animal Health (OIE) uses the cells for routine diagnosis of rabies. (see: http://www.oie.int/Eng/Normes/Mmanual/A_00044.htm) Tested and found negative for ectromelia virus (mousepox).

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C

Protocol:

- 1 Remove and discard culture medium.

2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. Add appropriate aliquots of the cell suspension to new culture vessels.
6. Incubate cultures at 37C.

Subculturing:

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: 1 to 2 times per week

Preservation:

Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase

Related Products:

Recommended medium (without the additional supplements or serum described under ATCC Medium): [ATCC 30-2003](#)

recommended serum: [ATCC 30-2020](#)
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca⁺⁺, Mg⁺⁺): [ATCC 30-2101](#)
Cell culture tested DMSO: [ATCC 4-X](#)

1023: Olmsted JB, et al. Isolation of microtubule protein from cultured mouse neuroblastoma cells. Proc. Natl. Acad. Sci. USA 65: 129-136, 1970. PubMed: [5263744](#)
22161: Klebe RJ, Ruddle FH. Neuroblastoma: Cell culture analysis of a differentiating stem cell system. J. Cell Biol. 43: 69A, 1969.

29352: Naslavsky N, et al. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J. Biol. Chem. 272: 6324-6331, 1997. PubMed: [9045652](#)

References:

29861: Kaneko K, et al. Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation. Proc. Natl. Acad. Sci. USA 94: 10069-10074, 1997. PubMed: [9294164](#)
32459: Maestrini E, et al. A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor. Proc. Natl. Acad. Sci. USA 93: 674-678, 1996. PubMed: [8570614](#)

[Return to Top](#)

Cell Biology

ATCC® Number: **CRL-2266™** Order this item Price: **\$264.00**
Designations: **SH-SY5Y** Depositors: JL Biedler
Biosafety Level: 1 Shipped: frozen
Medium & Serum: See Propagation Growth Properties: mixed, adherent and suspension epithelial
Organism: *Homo sapiens* (human) Morphology: 

Source: **Organ:** brain
Disease: neuroblastoma
Derived from metastatic site: bone marrow
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please [click here](#) for information regarding the specific requirements for shipment to your location.

Related Cell Culture Products

Restrictions: NOTE: SH-SY5Y was deposited at the ATCC by June L. Biedler, Memorial Sloan-Kettering Cancer Center. SH-SY5Y is distributed for academic research purposes only. Memorial Sloan-Kettering releases the line subject to the following: 1.) SH-SY5Y or its products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of SH-SY5Y including any use by a for-profit entity must first be negotiated with Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

Isolation: **Isolation date:** 1970
Applications: transfection host (Roche FuGENE® Transfection Reagents technology from amaxa)

Antigen Expression: Blood Type A; Rh+
Amelogenin: X
CSF1PO: 11
D13S317: 11
D16S539: 8,13
DNA Profile (STR): D5S818: 12
D7S820: 7,10
THO1: 7,10
TPOX: 8,11
vWA: 14,18

Cytogenetic Analysis: modal number = 47; the cells possess a unique marker comprised of a chromosome 1 with a complex insertion of an additional copy of a 1q segment into the long arm, resulting in trisomy of 1q [22554]

Age: 4 years
Gender: female

Comments: SH-SY5Y cells have a reported saturation density greater than 1 X 10(6) cells/sq cm. They are reported to exhibit moderate levels of dopamine beta hydroxylase activity [PubMed ID: 29704].

Propagation: **ATCC complete growth medium:** The base medium for this cell line is a 1:1 mixture of ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003, and F12 Medium. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Protocol: These cells grow as a mixture of floating and adherent cells. The cells grow as clusters of neuroblastic cells with multiple, short, fine cell processes (neurites). Cells will aggregate, form clumps and float.

Subculturing:

Remove the medium with the floating cells, and recover the cells by centrifugation. Rinse the adherent cells with fresh 0.25% trypsin, 0.53 mM EDTA solution, add an additional 1 to 2 ml of trypsin solution, and let the culture sit at room temperature (or at 37C) until the cells detach. Add fresh medium, aspirate, combine with the floating cells recovered above and dispense into new flasks.

Subcultivation Ratio: A subcultivation ratio of 1:20 to 1:50 is recommended

Medium Renewal: Every 4 to 7 days

Preservation:

Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO

Storage temperature: liquid nitrogen vapor phase

Doubling Time:

48 hrs

Related Products:

parental cell line: [ATCC HTB-11](#)
recommended serum: [ATCC 30-2020](#)

References:

22554: Ross RA, et al. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J. Natl. Cancer Inst. 71: 741-749, 1983. PubMed: [6137586](#)
23032: Biedler JL, et al. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res. 38: 3751-3757, 1978. PubMed: [29704](#)

[Return to Top](#)

Cell Biology

ATCC® Number: **CRL-1573™**  Price: **\$256.00**
 Designations: **293 [HEK-293]** Depositors: FL Graham
Biosafety Level: 2 [CELLS CONTAIN ADENOVIRUS] Shipped: frozen
 Medium & Serum: See Propagation Growth Properties: adherent
 epithelial
 Organism: *Homo sapiens* (human) Morphology: 

Source: **Organ:** embryonic kidney
Cell Type: transformed with adenovirus 5 DNA
 In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Permits/Forms:

Related Cell Culture Products

Restrictions: These cells are distributed for research purposes only. 293 cells, their products, or their derivatives may not be distributed to third parties.

Applications: efficacy testing [92587]
 transfection host (Nucleofection technology from Lonza Roche FuGENE® Transfection Reagents)
 viruscide testing [92579]

Receptors: vitronectin, expressed

Tumorigenic: Yes

DNA Profile (STR): Amelogenin: X
 CSF1PO: 11,12
 D13S317: 12,14
 D16S539: 9,13
 D5S818: 8,9
 D7S820: 11,12
 THO1: 7,9.3
 TPOX: 11
 vWA: 16,19

Cytogenetic Analysis: This is a hypotriploid human cell line. The modal chromosome number was 64, occurring in 30% of cells. The rate of cells with higher ploidies was 4.2 %. The der(1)t(1;15) (q42;q13), der(19)t(3;19) (q12;q13), der(12)t(8;12) (q22;p13), and four other marker chromosomes were common to most cells. Five other markers occurred in some cells only. The marker der(1) and M8 (or Xq+) were often paired. There were four copies of N17 and N22. Noticeably in addition to three copies of X chromosomes, there were paired Xq+, and a single Xp+ in most cells.

Age: fetus

Although an earlier report suggested that the cells contained Adenovirus 5 DNA from both the right and left ends of the viral genome [RF32764], it is now clear that only left end sequences are present. [39768]
 The line is excellent for titrating human adenoviruses.

Comments:	<p>The cells express an unusual cell surface receptor for vitronectin composed of the integrin beta-1 subunit and the vitronectin receptor alpha-v subunit. [23406] The Ad5 insert was cloned and sequenced, and it was determined that a colinear segment from nts 1 to 4344 is integrated into chromosome 19 (19q13.2). [39768]</p> <p>ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.</p>
Propagation:	<p>Atmosphere: air, 95%; carbon dioxide (CO₂), 5% Temperature: 37.0°C</p> <p>The cell line does not adhere to the substrate when left at room temperature for any length of time, therefore, live cultures may be received with the cells detached. The cells will re-attach to the flask over a period of several days in culture at 37C.</p> <p>Protocol:</p> <ol style="list-style-type: none"> 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. 3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
Subculturing:	<ol style="list-style-type: none"> 4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting. 5. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 2 X 10³ (3) to 6 X 10³ (3) viable cells/cm² is recommended. 6. Incubate cultures at 37°C. Subculture when cell concentration is between 6 and 7 X 10⁴ (4) cells/cm². <p>Subcultivation Ratio: 1:10 to 1:20 weekly. Medium Renewal: Every 2 to 3 days</p>
Preservation:	<p>Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase</p> <p>derivative: ATCC CRL-12006 derivative: ATCC CRL-12007 derivative: ATCC CRL-12013 derivative: ATCC CRL-12479 derivative: ATCC CRL-2029 derivative: ATCC CRL-2368</p>
Related Products:	<p>purified DNA: ATCC CRL-1573D Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC 30-2003 derivative: ATCC CRL-10852</p> <p>21624: Xie QW, et al. Complementation analysis of mutants of nitric oxide synthase reveals that the active site requires two hemes. Proc. Natl. Acad. Sci.</p>

Attachment 4

Bacteria used	Plasmid:	Plasmid	Source of plasmid	Gene Transfected	Change
E. coli	PEGFP GFP BAX	PEGFP	Clontech	Bax	Express GFP-Bax protein
E. coli	pCDNA3 FLAG - E2F1 WT	pCDNA-3	Invitrogen	E2F1	Express Flag-E2F1
E. coli	pBS SK II (+) BIM L	PEGFP-C1	Clontech	Bim-L	No Change
E. coli	pCEP Puma Ha	pCEP-4	Invitrogen	PUMA	Express HA-PUMA
E. coli	PRC - Bcl2 acta	PRC/CMV	Invitrogen	Bcl2 Acta	Express Bcl2-Acta
E. coli	PRC/CMV Bcl2 CB5 (664)	PRC/CMV	Invitrogen	Bcl2 CB5	Express Bcl2-CB5
E. coli	PCDNA3 (+) Mcl - I Flag	PCDNA-3.1	Invitrogen	Mcl-I	Express Flag-Mcl-1
E. coli	TP53INP1 (alpha) - pCDNA4	PCDNA-4	Invitrogen	TP-53-INP1 Alpha	Express TP53INP1(Alpha)
E. coli	TP53INP1β - pCDNA4	PCDNA-4	Invitrogen	TP-53-INP1 Beta	Express TP53INP1(Beta)
E. coli	TP53INP1 (alpha) - pEGFP	PEGFP-C1	Clontech	TP-53-INP1 Alpha	Express GFP-TP53INP1 Alpha
E. coli	TP53INP1β - pEGFP	PEGFP-C1	Clontech	TP-53-INP1 Beta	Express GFP-TP53INP1 Beta
E. coli	Lamp-1 GFP	PEGFP-C1	Clontech	LAMP-1	Express GFP-LAMP1
E. coli	Bcl-XL in GFP	PEGFP-C1	Clontech	Bcl-XL	Express GFP-Bcl-XL
E. coli	Bcl-2 in GFP	PEGFP-C1	Clontech	Bcl-2	Express GFP-Bcl2
E. coli	p3X Flag-NOXA	p3X-Flag-Myc-CMV	Sigma	NOXA	Express Flag-NOXA
E. coli	EGR-1 in 3X-Flag	p3X-Flag-Myc-CMV	Sigma	EGR-1	Express Flag-EGR1
E. coli	SP1 in pCDNA3	pCDNA-3	Invitrogen	SP-1	Express SP1
E. coli	CHOP in GFP	PEGFP-C1	Clontech	CHOP	Express GFP-CHOP
E. coli	ATF-4 in GFP	PEGFP-C1	Clontech	ATF-4	Express -GFP-ATF4
E. coli	GSK3-beta in pCDNA3	pCDNA-3	Invitrogen	GSK-3-Beta	Express GSK3-Beta
E. coli	FOXO3-CA in pCDNA3	pCDNA-3	Invitrogen	FOXO-3CA	Express FOXO3-CA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	pHA-PUMA in pEGFP	PEGFP-C1	Clontech	PUMA	Express GFP-PUMA
E. coli	Human EGR1DN in 3X Flag	p3X FLAG-CMV	Sigma	EGR1DN	Express FLAG-EGR1DN
E. coli	EGR-1 ZN Finger in 3X Flag	p3X FLAG-CMV	Sigma	EGR1-ZN Finger	Express FLAG-EGR1-Zn Finger
E. coli	SP1 in 3X Flag	p3X FLAG-CMV	Sigma	SP1	Express FLAG-SP1

1. IDENTIFICATION OF THE SUBSTANCE/ PREPARATION AND THE COMPANY/ UNDERTAKING

Product code
Product name

350717
PCDNA3.1/MYC-HIS A 20UG

Company/Undertaking Identification

INVITROGEN CORPORATON
5791 VAN ALLEN WAY
PO BOX 6482
CARLSBAD, CA 92008
760-603-7200

INVITROGEN CORPORATION
5250 MAINWAY DRIVE
BURLINGTON, ONT
CANADA L7L 6A4
800-263-6236

GIBCO PRODUCTS
INVITROGEN CORPORATION
3175 STALEY ROAD P.O. BOX 68
GRAND ISLAND, NY 14072
716-774-6700

2. COMPOSITION/ INFORMATION ON INGREDIENTS

Hazardous/Non-hazardous Components

The product contains no substances which at their given concentration, are considered to be hazardous to health. We recommend handling all chemicals with caution.

3. HAZARDS IDENTIFICATION

Emergency Overview

The product contains no substances which at their given concentration, are considered to be hazardous to health

Form
Solid

**Principle Routes of Exposure/
Potential Health effects**

Eyes
Skin

May cause eye irritation with susceptible persons.
No information available

3. HAZARDS IDENTIFICATION

Inhalation May cause irritation of respiratory tract.
Ingestion No information available

Specific effects

Carcinogenic effects No information available
Mutagenic effects No information available
Reproductive toxicity No information available
Sensitization No information available

Target Organ Effects No information available

HMIS

Health	0
Flammability	0
Reactivity	0

4. FIRST AID MEASURES

Skin contact Wash off immediately with plenty of water
Eye contact Rinse thoroughly with plenty of water, also under the eyelids.
Ingestion Never give anything by mouth to an unconscious person
Inhalation Move to fresh air
Notes to physician Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Dry chemical
Special protective equipment for firefighters Wear self-contained breathing apparatus and protective suit

6. ACCIDENTAL RELEASE MEASURES

Personal precautions Use personal protective equipment
Methods for cleaning up Soak up with inert absorbent material.

7. HANDLING AND STORAGE

Handling No special handling advice required
Storage Keep in properly labelled containers

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Occupational exposure controls

Exposure limits

Engineering measures Ensure adequate ventilation, especially in confined areas

Personal protective equipment

Respiratory protection In case of insufficient ventilation wear suitable respiratory equipment
Hand protection Protective gloves
Eye protection Safety glasses with side-shields
Skin and body protection Lightweight protective clothing.

Hygiene measures
Environmental exposure
controls

Handle in accordance with good industrial hygiene and safety practice
Prevent product from entering drains.

9. PHYSICAL AND CHEMICAL PROPERTIES

General Information

Form Solid

Important Health Safety and Environmental Information

Boiling point/range	°C No data available	°F No data available
Melting point/range	°C No data available	°F No data available
Flash point	°C No data available	°F No data available
Autoignition temperature	°C No data available	°F No data available
Oxidizing properties	No information available	
Water solubility	No data available	

10. STABILITY AND REACTIVITY

Stability	Stable.
Materials to avoid	No information available
Hazardous decomposition products	No information available
Polymerization	Hazardous polymerisation does not occur.

11. TOXICOLOGICAL INFORMATION

Acute toxicity

Principle Routes of Exposure/

Potential Health effects

Eyes	May cause eye irritation with susceptible persons.
Skin	No information available
Inhalation	May cause irritation of respiratory tract.
Ingestion	No information available

Specific effects

Carcinogenic effects	No information available
Mutagenic effects	No information available
Reproductive toxicity	No information available
Sensitization	No information available

Target Organ Effects No information available

12. ECOLOGICAL INFORMATION

Ecotoxicity effects	No information available.
Mobility	No information available.
Biodegradation	Inherently biodegradable.
Bioaccumulation	Does not bioaccumulate.

13. DISPOSAL CONSIDERATIONS

13. DISPOSAL CONSIDERATIONS

Dispose of in accordance with local regulations

14. TRANSPORT INFORMATION

IATA

Proper shipping name	Not classified as dangerous in the meaning of transport regulations
Hazard Class	No information available
Subsidiary Class	No information available
Packing group	No information available
UN-No	No information available

15. REGULATORY INFORMATION

International Inventories

U.S. Federal Regulations

SARA 313

This product is not regulated by SARA.

Clean Air Act, Section 112 Hazardous Air Pollutants (HAPs) (see 40 CFR 61)

This product does not contain HAPs.

U.S. State Regulations

California Proposition 65

This product does not contain chemicals listed under Proposition 65

WHMIS hazard class:

Non-controlled

This product has been classified according to the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR

16. OTHER INFORMATION

This material is sold for research and development purposes only. It is not for any human or animal therapeutic or clinical diagnostic use. It is not intended for food, drug, household, agricultural, or cosmetic use. An individual technically qualified to handle potentially hazardous chemicals must supervise the use of this material.

The above information was acquired by diligent search and/or investigation and the recommendations are based on prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be used only as a guide. All materials and mixtures may be present unknown hazards and should be used with caution. Since Invitrogen Corporation cannot control the actual methods, volumes, or conditions of use, the Company shall not be held liable for any damages or losses resulting from the handling or from contact with the product as described herein. THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

End of Safety Data Sheet

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : **p3xFLAG-Myc-CMV™-23 Expression Vector**

Product Number : E6026
Brand : Sigma

Company : Sigma-Aldrich Canada, Ltd
2149 Winston Park Drive
OAKVILLE ON L6H 6J8
CANADA

Telephone : +1 9058299500
Fax : +1 9058299292
Emergency Phone # : 800-424-9300

2. COMPOSITION/INFORMATION ON INGREDIENTS

CAS-No.	EC-No.	Index-No.	Concentration
Water			
7732-18-5	231-791-2	-	99.7558 %
2-Amino-2-(hydroxymethyl)propane-1,3-diol hydrochloride			
1185-53-1	214-684-5	-	0.157 %
Ethylenediaminetetraacetic acid disodium dihydrate			
6381-92-6	205-358-3	-	0.0372 %
Deoxyribonucleic acids, plasmid ColE1			
100209-25-4	309-333-9	-	0.05 %

3. HAZARDS IDENTIFICATION**WHMIS Classification**

Not WHMIS controlled.

Not WHMIS controlled.

HMS Classification

Health Hazard: 0

Flammability: 0

Physical hazards: 0

Potential Health Effects**Inhalation** May be harmful if inhaled. May cause respiratory tract irritation.**Skin** May be harmful if absorbed through skin. May cause skin irritation.**Eyes** May cause eye irritation.**Ingestion** May be harmful if swallowed.**4. FIRST AID MEASURES**

If inhaled

If breathed in, move person into fresh air. If not breathing give artificial respiration

In case of skin contact

Wash off with soap and plenty of water.

In case of eye contact

Flush eyes with water as a precaution.

If swallowed

Never give anything by mouth to an unconscious person. Rinse mouth with water.

5. FIRE-FIGHTING MEASURES**Flammable properties**

Flash point no data available

Ignition temperature no data available

Suitable extinguishing media

Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.

Special protective equipment for fire-fighters

Wear self contained breathing apparatus for fire fighting if necessary.

6. ACCIDENTAL RELEASE MEASURES**Personal precautions**

Avoid dust formation.

Environmental precautions

No special environmental precautions required.

Methods for cleaning up

Sweep up and shovel. Keep in suitable, closed containers for disposal.

7. HANDLING AND STORAGE**Handling**

Provide appropriate exhaust ventilation at places where dust is formed. Normal measures for preventive fire protection.

Storage

Keep container tightly closed in a dry and well-ventilated place.

Recommended storage temperature: -20 °C

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Contains no substances with occupational exposure limit values.

Personal protective equipment**Respiratory protection**

Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Hand protection

For prolonged or repeated contact use protective gloves.

Eye protection

Safety glasses

Hygiene measures
General industrial hygiene practice.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Form solid

Safety data

pH no data available
Melting point no data available
Boiling point no data available
Flash point no data available
Ignition temperature no data available
Lower explosion limit no data available
Upper explosion limit no data available
Water solubility no data available

10. STABILITY AND REACTIVITY

Storage stability

Stable under recommended storage conditions.

Hazardous decomposition products

Hazardous decomposition products formed under fire conditions. - Nature of decomposition products not known.

11. TOXICOLOGICAL INFORMATION

Acute toxicity

no data available

Irritation and corrosion

no data available

Sensitisation

no data available

Chronic exposure

IARC: No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Potential Health Effects

Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Ingestion May be harmful if swallowed.

12. ECOLOGICAL INFORMATION

Elimination information (persistence and degradability)

MAX EFFICIENCY DH5ALPHA' IQ COMPETENT CELLS
 INVITROGEN CORPORATION
 MSDS ID: 18288

1. PRODUCT AND COMPANY INFORMATION

INVITROGEN CORPORATION
 1600 FARADAY AVE.
 CARLSBAD, CA 92008
 760/603-7200

GIBCO PRODUCTS
 INVITROGEN CORPORATION
 3175 STALEY ROAD P.O. BOX 68
 GRAND ISLAND, NY 14072
 716/774-6700

INVITROGEN CORPORATION
 3 FOUNTAIN DR.
 INCHINNAN BUSINESS PARK
 PAISLEY, PA4 9RF
 SCOTLAND
 44-141 814-6100

INVITROGEN CORPORATION
 P.O. BOX 12-502
 PENROSE
 AUCKLAND 1135
 NEW ZEALAND
 64-9-579-3024

INVITROGEN CORPORATION
 2270 INDUSTRIAL ST.
 BURLINGTON, ONT
 CANADA L7P 1A1
 905/335-2255

EMERGENCY NUMBER (SPILLS, EXPOSURES): 301/431-8585 (24 HOUR)
 800/451-8346 (24 HOUR)
 800/955-6288

NON-EMERGENCY INFORMATION:

Product Name:
 MAX EFFICIENCY DH5ALPHA' IQ COMPETENT CELLS

NOTE: If this product is a kit or is supplied with more than one material, please refer to the MSDS for each component for hazard information.

Product Use:
 These products are for laboratory research use only and are not intended for human or animal diagnostics, therapeutic, or other clinical uses.

Synonyms:
 Not available.

2. COMPOSITION, INFORMATION ON INGREDIENTS

The following list shows components of this product classified as hazardous based on physical properties and health effects:

Component	CAS No.	Percent
DIMETHYL SULFOXIDE	67-68-5	3 - 7
GLYCEROL	56-81-5	7 - 13

MATERIAL SAFETY DATA SHEET
Page 2 of 8
Revised 9/03/02
Replaces 6/19/02
Printed 9/10/02

MAX EFFICIENCY DHSALPHAF'IQ COMPETENT CELLS
INVITROGEN CORPORATION
MSDS ID: 18288

3. HAZARDS IDENTIFICATION

***** EMERGENCY OVERVIEW *****

Warning!
Irritant:
Harmful if absorbed.

Potential Health Effects:
Eye:
Can cause moderate irritation, tearing and reddening, but not likely to permanently injure eye tissue.

Skin:
Can cause moderate skin irritation, defatting, and dermatitis. Not likely to cause permanent damage.
Upon prolonged or repeated exposure, harmful if absorbed through the skin.
May cause minor systemic damage.

Inhalation:
Can cause moderate respiratory irritation, dizziness, weakness, fatigue, nausea and headache.
No toxicity expected from inhalation.

Ingestion:
Irritating to mouth, throat, and stomach. Can cause abdominal discomfort, nausea, vomiting and diarrhea.

Chronic:
No data on cancer.

4. FIRST AID MEASURES

Eye:
Flush eyes with plenty of water for at least 20 minutes retracting eyelids often. Tilt the head to prevent chemical from transferring to the uncontaminated eye. Get immediate medical attention.

Skin:
Wash with soap and water. Get medical attention if irritation develops or persists.

Inhalation:
Remove to fresh air. If breathing is difficult, have a trained individual administer oxygen. If not breathing, give artificial respiration and have a trained individual administer oxygen. Get medical attention immediately.

Ingestion:
Do not induce vomiting and seek medical attention immediately. Drink two

MATERIAL SAFETY DATA SHEET

MAX EFFICIENCY DHSALPHAF'IQ COMPETENT CELLS
 INVITROGEN CORPORATION
 MSDS ID: 18288

Page 4 of 8
 Revised 9/03/02
 Replaces 6/19/02
 Printed 9/10/02

6. ACCIDENTAL RELEASE MEASURES (CONT.)

the expertise of employees in the area responding to the spill. Ventilate the contaminated area. Prevent the spread of any spill to minimize harm to human health and the environment if safe to do so. Wear complete and proper personal protective equipment following the recommendation of Section VIII at a minimum. Dike with suitable absorbent material like granulated clay. Gather and store in a sealed container pending a waste disposal evaluation.

7. HANDLING AND STORAGE

Storage of some materials is regulated by federal, state, and/or local laws.

Storage Pressure:
 Ambient

Handling Procedures:
 Harmful or irritating material. Avoid contacting and avoid breathing the material. Use only in a well ventilated area. Keep closed or covered when not in use.

Storage Procedures:
 Store in a cool dry ventilated location. Isolate from incompatible materials and conditions. Keep container(s) closed. Suitable for most general chemical storage areas.

8. EXPOSURE CONTROLS, PERSONAL PROTECTION

Exposure Limits:

Component	OSHA PEL (ppm)	AGCIIH TWA (ppm)
DIMETHYL SULFOXIDE	Not established.	Not established.
GLYCEROL	15	10 MG/M3

Engineering Controls:
 Local exhaust ventilation or other engineering controls are normally required when handling or using this product to avoid overexposure.

Personal Protective Equipment:

Eye:
 An eye wash station must be available where this product is used. Wear chemically resistant safety glasses with side shields when handling this product. Wear additional eye protection such as chemical splash goggles and/or face shield when the possibility exists for eye contact with splashing or spraying liquid, or airborne material. Do not wear contact lenses. Have an eye wash station available.

MATERIAL SAFETY DATA SHEET

Page 5 of 8
 Revised 9/03/02
 Replaces 6/19/02
 Printed 9/10/02

MAX EFFICIENCY DHSALPHA'IQ COMPETENT CELLS
 INVITROGEN CORPORATION
 MSDS ID: 18288

8. EXPOSURE CONTROLS, PERSONAL PROTECTION (CONT.)

Skin:
 Avoid skin contact by wearing chemically resistant gloves, an apron and other protective equipment depending upon conditions of use. Inspect gloves for chemical break-through and replace at regular intervals. Clean protective equipment regularly. Wash hands and other exposed areas with mild soap and water before eating, drinking, and when leaving work. Have a safety shower available.

Respiratory:
 Use supplied-air respiratory equipment as required.
 NIOSH approved air purifying respirator with dust/mist filter.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance/physical state: Liquid solution / suspension
 Odor: No odor.
 Boiling Point (C): Not established.
 Melting Point (C): Not established.
 Solubility in water: Not established.
 pH: Not established.
 Vapor Pressure: Not established.
 Vapor Density: Not established.
 Specific Gravity/Density: Not established.
 Octanol/water Partition Coeff: Not established.
 Volatiles: Not established.
 Evaporation Rate: Not established.
 Viscosity: Not established.

10. STABILITY AND REACTIVITY

Stability:
 Stable under normal conditions.

Conditions to Avoid:
 Strong oxidizing agents. Temperatures above the high flash point of this combustible material in combination with sparks, open flames, or other sources of ignition. Strong alkalis. Temperatures above flash point in combination with sparks, open flames, or other sources of ignition.

Hazardous Decomposition Products:
 Carbon monoxide. Carbon dioxide. Sulfur containing gases.

Hazardous Polymerization:
 Hazardous polymerization will not occur.

MAX EFFICIENCY DHSALPHA IQ COMPETENT CELLS
INITROGEN CORPORATION
MSDS ID: 18288

11. TOXICOLOGICAL INFORMATION

Acute Toxicity:

Dermal/Skin:
DIMETHYL SULFOXIDE: 40 GM/KG

Inhalation/Respiratory:
Not determined.

Oral/Ingestion:
DIMETHYL SULFOXIDE: 14,500 MG/KG
Glycerol: 12600 MG/KG

Target Organs: Blood. Eyes. Skin. Kidneys.

Carcinogenicity:

NTP:
Not tested.

IARC:
Not listed.

OSHA:
Not regulated.

Other Toxicological Information

12. Ecological Information

Ecotoxicological Information: No ecological information available.

Environmental Fate (Degradation, Transformation, and Persistence):
Bioconcentration is not expected to occur.
Biodegrades quickly.

13. DISPOSAL CONSIDERATIONS

Regulatory Information:
Not applicable.

Disposal Method:
Clean up and dispose of waste in accordance with all federal, state, and local environmental regulations.
Dispose of by incineration following Federal, State, Local, or Provincial regulations.

MATERIAL SAFETY DATA SHEET Page 7 of 8
 Revised 9/03/02
 Replaces 6/19/02
 Printed 9/10/02

MAX EFFICIENCY DHSALPHA IQ COMPETENT CELLS
 INVITROGEN CORPORATION
 MSDS ID: 18286

14. TRANSPORT INFORMATION

Proper Shipping Name: Not Determined.
 Hazard Class:
 Subsidiary Hazards:
 ID Number:
 Packing Group:

15. REGULATORY INFORMATION

UNITED STATES:

TSCA:
 This product is solely for research and development purposes only and may not be used, processed or distributed for a commercial purpose. It may only be handled by technically qualified individuals.

Prop 65 Listed Chemicals: PROP 65 PERCENT
 NO Prop 65 Chemicals.

No 313 Chemicals

CANADA:

DSL/NDSL:
 Not determined.

COMPONENT
 DIMETHYL SULFOXIDE
 GLYCEROL

WHMIS Classification
 D2B
 D2B

EUROPEAN UNION:

PRODUCT RISK PHRASES: None assigned.
 PRODUCT SAFETY PHRASES: None assigned.
 PRODUCT CLASSIFICATION: Not classified.

Component
 DIMETHYL SULFOXIDE
 GLYCEROL

EINECS
 Number
 200-664-3
 200-289-5

MAX EFFICIENCY DEHALPHAF'IQ COMPETENT CELLS
 INVITROGEN CORPORATION
 MSDS ID: 18288

16. OTHER INFORMATION

HMIS Rating 0-4:
 FIRE: Not determined.
 HEALTH: Not determined.
 REACTIVITY: Not determined.

- Abbreviations
 N/A - Data is not applicable or not available
 SARA - Superfund and Reauthorization Act
 HMIS - Hazard Material Information System
 WHMIS - Workplace Hazard Materials Information System
 NTP - National Toxicology Program
 OSHA - Occupational Health and Safety Administration
 IARC - International Agency for Research on Cancer
 PROP 65 - California Safe Drinking Water and
 Toxic Enforcement Act of 1986
 EINECS - European Inventory of Existing Commercial
 Chemical Substances

The above information was acquired by diligent search and/or investigation and the recommendations are based on prudent application of professional judgment. The information shall not be taken as being all inclusive and is to be used only as a guide. All materials and mixtures may present unknown hazards and should be used with caution. Since Invitrogen Corporation cannot control the actual methods, volumes, or conditions of use, the Company shall not be held liable for any damages or losses resulting from the handling or from contact with the product as described herein. THE INFORMATION IN THIS MSDS DOES NOT CONSTITUTE A WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.



Office of Biohazard Containment and Safety
Science Branch, CFIA
59 Camelot Drive, Ottawa, Ontario K1A 0Y9
Tel: (613) 221-7068 Fax: (613) 228-6129
Email: ImportZoopath@inspection.gc.ca

Bureau du confinement des biorisques et sécurité
Direction générale des sciences, ACIA
59 promenade Camelot, Ottawa, Ontario K1A 0Y9
Tél: (613) 221-7068 Téléc: (613) 228-6129
Courriel: ImportZoopath@inspection.gc.ca

October 20th, 2009

Ms. Shamila Survery / Mr. Michael Decosimo
Cedarlane Laboratories Ltd
4410 Paletta Court
Burlington, Ontario L7L 5R2

By Facsimile: (289) 288-0020

SUBJECT: Importation of *Escherichia coli* strains

Dear Ms. Survery / Mr. Decosimo:

Our office received your query about the importation of *Escherichia coli* from the American Type Culture Collection (ATCC) located in Manassas, Virginia, United States. The following *Escherichia coli* strains are considered to be level 1 animal pathogens:

- 5K
- 58
- 58-161
- 679
- 1532
- AB284
- AB311
- AB1157
- AB1206
- AG1
- B
- BB4
- BD792
- BL21
- BL21 (DE3)
- BM25.8
- C
- C-1a
- C-3000
- C25
- C41 (DE3)
- C43 (DE3)
- C600
- Cavalli Hfr
- CIE85
- DH1
- DH10 GOLD
- DH10B
- DH5
- **DH5-alpha**
- DP50
- DY145
- DY380
- E11
- EJ183
- EL250
- EMG2
- EPI 300
- EZ10
- FDA Seattle 1946
- Fusion-Blue
- H1443
- HF4714
- HB101
- HS(PFAMP)R
- Hfr3000
- Hfr3000 X74
- HMS174
- J52
- J53
- JC3272
- JC7661
- JC9387
- JF1504
- JF1508
- JF1509
- JJ055
- JM83
- JM101
- JM109
- K12
- KC8
- KA802
- KAM32
- KAM33
- KAM43
- LE450
- LE451
- LE452
- MB408
- MBX1928
- MC1061
- MC4100 (MuLac)
- MG1655
- MM294
- MS101
- NC-7
- Nissle 1917
- One Shot STBL3
- OP50
- P678
- PA309
- PK-5
- PMC103
- PR13
- Rri
- RV308
- S17-1λ -PIR
- SCS1
- SMR10
- SOLR
- SuperchargeEZ10
- SURE
- TOP10
- TG1
- U5/41
- W208
- W945
- W1485
- W3104
- W3110
- WA704
- WP2
- X1854
- X2160T
- X2541
- X2547T
- XL1-BLUE
- XL1-BLUE-MRF
- XL0LR
- Y10
- Y1090 (1090)
- YN2980
- W3110
- WG1
- WG439
- WG443
- WG445

The Office of Biohazard Containment and Safety (BCS) of the Canadian Food Inspection Agency (CFIA) only issues import permits for microorganisms that are pathogenic to animals, or parts of microorganisms that are pathogenic to animals. As the products listed above are not considered pathogenic to animals, the Office of BCS does not have any regulatory requirements for their importation.

Please note that other legislation may apply. You may wish to contact the Public Health Agency of Canada's (PHAC) Office of Laboratory Security at (613) 957-1779.

Note: Microorganisms pathogenic to animals and veterinary biologics require an import permit from the CFIA.

Sincerely,

Cinthia Labrie
Head, Animal Pathogen Importation Program
Office of Biohazard Containment & Safety